Development News Edition
Give Feedback

AstraZeneca's key lung cancer drug wins European panel thumbs-up

Reuters Health News Summary

Reuters 28 Jul 2018, 12:58 PM
  • GSK's severe pediatric asthma drug wins European panel thumbs-up (Image Credit: Reuters)

Following is a summary of current health news briefs.

AstraZeneca's key lung cancer drug wins European panel thumbs-up

AstraZeneca's cancer drug Imfinzi has won a key recommendation from a European Medicines Agency (EMA) panel less than six months after the first global approvals in Western markets. EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Imfinzi, an immunotherapy drug already boosting sales for the British drugmaker, for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

China says vaccine maker Changsheng broke manufacturing rules, faked records: Xinhua

China's cabinet investigation group has found that vaccine maker Changsheng Biotechnology broke the law in manufacturing rabies vaccines, the state news agency Xinhua reported on Friday. The investigation group said the company had systematically falsified production and testing records to avoid regulatory scrutiny, according to Xinhua.

Shingrix vaccine makes shingles less severe, disruptive to quality of life

The vaccine Shingrix prevents shingles, and if people do contract the virus, it reduces the severity of illness, two company-funded study suggests. Shingles, also known as herpes zoster, typically develops in older adults who had chicken pox, or the varicella-zoster virus, when they were younger. Its hallmark is a painful rash, which clears up within a month in most cases. In some instances, however, it leads to nerve pain that can linger for much longer and make it harder for people to manage daily tasks.

Bayer hits back at new Netflix medical device documentary

Bayer AG disputed accusations in a new Netflix documentary that claims medical device makers and the U.S. Food and Drug Administration placed profits before patient safety. The company, in a statement released Thursday night, said the documentary "The Bleeding Edge," which debuted on the streaming site on Friday, lacks scientific support and cherry-picked facts to present an inaccurate and misleading picture of Bayer's permanent birth control device Essure, one of the products spotlighted in the film.

High calibre guns more deadly

(Reuters Health) - Shots from high calibre firearms are more likely to kill, a new study suggests. Researchers wading into the gun control debate have shown that people shot by criminals wielding a higher calibre gun are more likely to die than those shot with a small calibre weapon, according to a report in JAMA Network Open.

FDA declines to approve Insys Therapeutic's opioid painkiller

Insys Therapeutics Inc said on Friday the U.S. Food and Drug Administration declined to approve its opioid painkiller, citing potential safety concerns. Insys shares slid nearly 9 per cent to $6.62 on Friday, hitting their lowest level in more than two months.

GSK's severe pediatric asthma drug wins European panel thumbs-up

GlaxoSmithKline drug Nucala has won a key recommendation from a European Medicines Agency (EMA) panel for use in the treatment of children with severe asthma, the company said in a statement on Friday. The EMA's Committee for Medicinal Products for Human Use (CHMP) recommended Nucala for use as an add-on treatment for severe refractory eosinophilic asthma in pediatric patients aged six up to 17 years, it said.

Bayer wins EU watchdog's endorsement for wider Xarelto use

Bayer won the European Medicines Agency's (EMA) recommendation for widening the use of its blockbuster clot prevention drug Xarelto to include atherosclerosis patients, opening a potentially lucrative new market. The German drugmaker, which bought U.S. seed maker Monsanto, has said about 30 million additional patients could potentially benefit from the drug if the wider use gets the nod.

Teen drivers take more risks after trading learner permits for licenses

Adolescents may be cautious while they're learning to drive, but a new study suggests they get downright dangerous once their license allows them to hit the road without a grownup in the car. Teen drivers have long been synonymous with risky manoeuvres on the road and plenty of previous research has also found novice drivers have higher crash rates than people with more experience. The current study helps pinpoint when teen driving may be riskiest by using cameras and sensors inside cars to examine driving habits for parents and children over almost two years, starting when teens got their learner's permits.

GSK to shut Bangladesh drug-making factory by end-2018

GlaxoSmithKline will shut its drug manufacturing operations in Bangladesh by the end of this year and will continue with its healthcare business, the managing director of its local businesses said on Friday. Globally GSK's pharmaceuticals business has seen sluggish growth in recent years. The company on Wednesday unveiled a new restructuring program to deliver annual cost savings of 400 million pounds by 2021.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)

add banner